Methods and Outreach, Novo Nordisk Pharma, Madrid, Spain.
Stat Med. 2024 Sep 30;43(22):4217-4249. doi: 10.1002/sim.10111.
In evidence synthesis, effect modifiers are typically described as variables that induce treatment effect heterogeneity at the individual level, through treatment-covariate interactions in an outcome model parametrized at such level. As such, effect modification is defined with respect to a conditional measure, but marginal effect estimates are required for population-level decisions in health technology assessment. For noncollapsible measures, purely prognostic variables that are not determinants of treatment response at the individual level may modify marginal effects, even where there is individual-level treatment effect homogeneity. With heterogeneity, marginal effects for measures that are not directly collapsible cannot be expressed in terms of marginal covariate moments, and generally depend on the joint distribution of conditional effect measure modifiers and purely prognostic variables. There are implications for recommended practices in evidence synthesis. Unadjusted anchored indirect comparisons can be biased in the absence of individual-level treatment effect heterogeneity, or when marginal covariate moments are balanced across studies. Covariate adjustment may be necessary to account for cross-study imbalances in joint covariate distributions involving purely prognostic variables. In the absence of individual patient data for the target, covariate adjustment approaches are inherently limited in their ability to remove bias for measures that are not directly collapsible. Directly collapsible measures would facilitate the transportability of marginal effects between studies by: (1) reducing dependence on model-based covariate adjustment where there is individual-level treatment effect homogeneity or marginal covariate moments are balanced; and (2) facilitating the selection of baseline covariates for adjustment where there is individual-level treatment effect heterogeneity.
在证据综合中,效应修饰因子通常被描述为通过在个体水平上参数化的结局模型中的治疗-协变量相互作用在个体水平上引起治疗效果异质性的变量。因此,效应修饰是相对于条件度量来定义的,但在健康技术评估中,需要进行人群水平决策的边际效应估计。对于不可折叠的措施,即使在个体水平的治疗效果同质的情况下,那些不是个体水平的治疗反应决定因素的纯粹预后变量也可能修饰边际效应。在存在异质性的情况下,对于不能直接折叠的措施的边际效应不能用边际协变量矩来表示,并且通常取决于条件效应修饰因子和纯粹预后变量的联合分布。这对证据综合中的推荐实践有影响。在缺乏个体水平的治疗效果异质性的情况下,或者在研究之间的边际协变量矩平衡的情况下,未调整的锚定间接比较可能存在偏倚。可能需要进行协变量调整,以解释涉及纯粹预后变量的联合协变量分布在研究之间的不平衡。在缺乏目标的个体患者数据的情况下,由于不能直接折叠的措施的协变量调整方法在去除偏倚的能力上存在固有限制,因此协变量调整方法是有限的。直接可折叠的措施将通过以下方式促进边际效应在研究之间的可转移性:(1) 在个体水平的治疗效果同质或边际协变量矩平衡的情况下,减少对基于模型的协变量调整的依赖;(2) 促进在存在个体水平的治疗效果异质性的情况下为调整选择基线协变量。